Form 4: Cellectar Biosciences CFO Receives Stock Options

Cellectar Biosciences CFO Chad Kolean was granted stock options for 92,000 shares, contingent on stockholder approval which was obtained on July 7, 2026.

Summary

• Chad Kolean, CFO of Cellectar Biosciences, Inc., was granted stock options for 92,000 shares.
• The grant was contingent on stockholder approval of the company's amended 2021 Stock Incentive Plan, which was obtained on July 7, 2026.
• The stock options have an exercise price of $3.14 per share.
• The options vest over a three-year period starting from May 28, 2026, with one-third vesting on the first anniversary and the remainder vesting monthly thereafter.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details a standard executive compensation event (stock option grant) rather than significant financial performance or strategic shifts.

Positives

• Grant of stock options to CFO, indicating potential alignment of management incentives with company performance.
• Stockholder approval for the incentive plan was successfully obtained, suggesting a positive governance outcome.
• Vesting schedule over three years encourages long-term commitment from the CFO.

Negatives

• The exercise price of $3.14 per share is a key factor for future profitability of these options.
• The options are contingent, meaning their ultimate value depends on future stock performance and plan approval.

Risks

• The value of the stock options is subject to market fluctuations and the future performance of Cellectar Biosciences.
• The vesting schedule means the full benefit of the options is not realized immediately, tying compensation to continued employment and company success.

Future Outlook

The stock options granted to the CFO are subject to a three-year vesting schedule, indicating a long-term incentive tied to the company's future performance and the executive's continued tenure.

Industry Context

StockSavvy.ai notes that the granting of stock options to key executives like a CFO is a common practice in the biotechnology sector to attract and retain talent, aligning their financial interests with shareholder value.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to the CFO aligns executive compensation with potential future stock appreciation, but also represents potential dilution if options are exercised.
• Employees: The approval of the incentive plan may pave the way for broader employee stock option grants.
• Management: The CFO receives a financial incentive tied to the company's long-term success.

Next Steps

• The stock options will vest over a three-year period from May 28, 2026.
• The CFO will continue to hold the options, with their ultimate value dependent on the company's stock performance.

Key Dates

Keywords

stock options, Cellectar Biosciences, CLRB, CFO, Chad Kolean, incentive plan, beneficial ownership, SEC Form 4